Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form of Ruvidar for the treatment of glio blastoma multiforme, a form of brain cancer, non-small cell lung cancer, pancreatic cancer, colorectal cancer, and muscle invasive bladder cancer; and Ruvidar, a topical treatment for herpes simplex virus-1 lesions and an extracorporeal treatment for lymphoma, leukemia, and multiple myeloma. The company also researches, develops, manufactures, and distributes Cool Laser Therapy systems to healthcare practitioners for the healing of pain. Theralase Technologies Inc. is based in Toronto, Canada.…
3 Canadian Growth Stocks To Watch In November 2026
Theralase Technologies (CVE: TLT) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Medical Devices industry, part of the Healthcare sector.
The shares were at 0.1750 CAD on 20 November 2026, down 12.5% over 52 weeks. Its 52-week range is 0.1500 CAD to 0.4100 CAD: the price is 57.3% below the high and 16.7% above the low.
Its market capitalisation is 54.33M CAD.
Theralase Technologies reports return on equity of -231.8%, an operating margin of -474.3% and revenue down 25.2% year over year.
It holds more cash than debt, a net cash position of 5.11M CAD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 23 November 2026.